Venus Remedies Q1 Results FY27: What to Expect
- June 30, 2026
- Posted by: Kunal Singla
- Category: News
Venus Remedies Q1 Results FY27: Revenue Rs 172 Cr (+25.7% YoY) | PAT Rs 15 Cr (+50.0% YoY). Uniresearch Q1 results preview.
This Venus Remedies Q1 results preview is based on Screener.in consolidated quarterly financials for the Q1 FY26 base quarter, with the Uniresearch trailing-growth model applied to project the Q1 FY27 estimate. Venus Remedies reported Revenue of Rs 137 Cr and PAT of Rs 10 Cr in Q1 FY26, forming the base for the Venus Remedies Q1 Results FY27 forecast of Rs 172 Cr Revenue and Rs 15 Cr PAT. Prepared by Ankit Jaiswal, Senior Research Analyst.
Click Here – Get Free Investment Predictions
Venus Remedies Q1 Results FY27: Uniresearch Prediction
| Metric | Q1 FY26 Actual | Q1 FY27 Uniresearch Prediction | YoY Change |
|---|---|---|---|
| Revenue (Rs Cr) | 137 | 172 | +25.7% |
| PAT (Rs Cr) | 10 | 15 | +50.0% |
Source: Q1 FY26 actuals from Screener.in. Q1 FY27 prediction for Venus Remedies applies Uniresearch trailing growth rates (Revenue +25.7%, PAT +50.0%) to Q1 FY26 verified actuals.
Track Venus Remedies Live on Univest Screener
Venus Remedies Q1 Results FY27 Preview: Expectations, Results Date and Latest News
The Venus Remedies Q1 results expectations for FY27 point to Revenue of Rs 172 Cr (+25.7% YoY) and PAT of Rs 15 Cr (+50.0% YoY), based on the Venus Remedies Q1 Results FY27 Uniresearch estimate. These Venus Remedies Q1 results expectations assume the growth trajectory from Q1 FY26 continues into Q1 FY27, supported by sector tailwinds in pharmaceuticals. Investors can use this Venus Remedies Q1 results preview as a directional reference ahead of the official result declaration.
The Venus Remedies Q1 results date is not yet officially announced. Typically, Q1 results dates for NSE-listed companies are disclosed via a board meeting notice on the NSE or BSE filing portal, shortly after Q1 FY27 ends. For the latest news on Venus Remedies Q1 results FY26-27, track the Univest Screener and NSE filing alerts. Once the Venus Remedies Q1 results date is confirmed, compare actual Venus Remedies results against this Venus Remedies Q1 Results FY27 preview.
Q4 FY26 Performance: Context for the Venus Remedies Q1 Results FY27 Preview
The Venus Remedies Q1 Results FY27 preview is anchored on Q4 FY26 consolidated Revenue of Rs 259 Cr and PAT of Rs 48 Cr. These Q4 FY26 actuals, combined with Uniresearch trailing growth estimates, form the basis of the Q1 FY27 Uniresearch projection for Venus Remedies projection.
The sequential comparison also provides useful context. Q4 FY26 Revenue of Rs 259 Cr reflects year-end cycles that may not repeat equally in Q1 FY27. The more meaningful benchmark is the year-on-year comparison against Q1 FY26 Revenue of Rs 137 Cr, where the Venus Remedies Q1 results expectations target +25.7% growth.
Uniresearch Estimate Behind the Venus Remedies Q1 Results FY27 Projection
The Q1 FY27 prediction for Venus Remedies is derived from Uniresearch trailing analysis, which estimates Q1 FY27 Revenue growth of +25.7% and PAT growth of +50.0% YoY. These trailing rates are applied to Q1 FY26 actuals to arrive at the projection of Rs 172 Cr Revenue and Rs 15 Cr PAT.
The Q1 FY27 estimation methodology for Venus Remedies applies full-year FY27 trailing growth rates (+25.7% Revenue, +50.0% PAT) uniformly to Q1 FY26 actuals. This approach assumes the quarterly trajectory broadly mirrors the full-year trend. Treat this Q1 results preview as a directional benchmark, not a guaranteed outcome.
Get Expert Stock Picks on Univest
Venus Remedies Q1 Results FY27 Expectations: Key Watchpoints
Revenue vs the Uniresearch Estimate
Whether Venus Remedies results deliver Revenue in line with the Rs 172 Cr Venus Remedies Q1 Results FY27 Uniresearch estimate (+25.7% YoY). Q4 FY26 Revenue was Rs 259 Cr.
PAT Margin Sustainability
PAT of Rs 15 Cr (+50.0% YoY) is the Venus Remedies Q1 Results FY27 Uniresearch estimate. Q4 FY26 PAT was Rs 48 Cr. Margin stability in Venus Remedies results signals operating leverage.
Management Commentary and Full-Year FY27 Guidance
Beyond the headline Venus Remedies Q1 results, management commentary will be watched for full-year FY27 guidance on revenue trajectory, margin direction, and capital allocation.
Risks to the Venus Remedies Q1 Results FY27 Prediction
Below-Estimate Revenue Growth
If actual Venus Remedies Q1 results Revenue underperforms the +25.7% growth target, the Rs 172 Cr Venus Remedies Q1 Results FY27 prediction would be revised downward.
PAT Pressure from Costs or Provisions
One-time charges, elevated provisions, or margin headwinds could push Venus Remedies results PAT below Rs 15 Cr in Q1 FY27.
External and Macro Environment
Macro risks including commodity price movements, rupee volatility, interest rate changes, and FII/DII sentiment shifts could create downside risk in Venus Remedies results even if company-specific execution remains on track.
Venus Remedies Q1 Results FY26-27: Sector Growth Drivers and Latest News
The latest news on Venus Remedies Q1 results FY26-27 from a sector perspective shows that pharmaceuticals is navigating the following growth drivers heading into Q1 FY27. Investors tracking Venus Remedies Q1 results should monitor these sector-level trends.
Domestic Formulation Growth
India’s domestic pharma market grows at 8-10% annually, led by chronic therapies.
Regulated Market Export Pipeline
USFDA-approved facilities and a growing ANDA pipeline offer incremental export revenues.
Use Univest Screener to Track Venus Remedies Live
Venus Remedies Q1 Results FY27: What to Expect
The Q1 FY27 Uniresearch projection of Venus Remedies Revenue Rs 172 Cr and PAT Rs 15 Cr covers the complete Venus Remedies Q1 results preview, including expectations, risks, and sector outlook. Track the Venus Remedies Q1 results date confirmation on the Univest Screener for timely updates.
Once the Venus Remedies results are declared, compare them against this Uniresearch preview to assess beat, meet, or miss. Access expert research and screener tools on Univest to stay updated.
Download the Univest iOS App or Univest Android App for live Venus Remedies Q1 FY27 result alerts.
Disclaimer: Revenue and PAT actuals sourced from Screener.in consolidated quarterly financial data. Q1 FY27 projections are derived from Uniresearch trailing growth rates applied to Q1 FY26 actuals. These are Uniresearch trailing estimates, not guaranteed outcomes. Investments are subject to market risk. For educational purposes only. SEBI RA INH000013776.
Frequently Asked Questions on Venus Remedies Q1 Results FY27
What is the Uniresearch prediction for Venus Remedies Q1 Results FY27?
Ans. Uniresearch projects Q1 FY27 Revenue for Venus Remedies at Rs 172 Cr (+25.7% YoY) and PAT at Rs 15 Cr (+50.0% YoY), based on trailing analysis of Q1 FY26 actuals (Revenue Rs 137 Cr, PAT Rs 10 Cr). This Q1 FY27 estimate for Venus Remedies is directional, not a guaranteed outcome.
What are the Venus Remedies Q1 Results FY27 expectations?
Ans. The Q1 FY27 expectations for Venus Remedies are Revenue Rs 172 Cr (+25.7% YoY) and PAT Rs 15 Cr (+50.0% YoY), per the Uniresearch trailing-growth estimate. These Venus Remedies Q1 results expectations are based on Q1 FY26 actuals from Screener.in.
What were the Q4 FY26 actuals behind the Venus Remedies Q1 Results FY27 projection?
Ans. Q4 FY26 consolidated Revenue was Rs 259 Cr and PAT was Rs 48 Cr, serving as the most recent sequential reference for this Q1 FY27 preview of Venus\ Remedies.
How reliable is the Venus Remedies Q1 Results FY27 Uniresearch prediction?
Ans. The Q1 FY27 results preview for Venus Remedies is a Uniresearch trailing projection, not a guaranteed outcome. Actual results may differ due to macro conditions, seasonal variation, and company-specific execution. Use the projection as a directional benchmark.
What base data is used for the Venus Remedies Q1 Results FY27 Uniresearch projection?
Ans. The Venus Remedies Q1 Results FY27 projection uses Q1 FY26 consolidated actuals (Revenue Rs 137 Cr, PAT Rs 10 Cr) from Screener.in, with trailing growth rates (+25.7% Revenue, +50.0% PAT) applied to derive the estimate.
What are the key risks to the Venus Remedies Q1 Results FY27 estimate?
Ans. Key risks to the Q1 FY27 results of Venus\ Remedies include usfda regulatory risk, us generic pricing erosion, and broader macro headwinds that could cause actual Venus Remedies results to undershoot the Uniresearch Q1 results preview.
When will Venus Remedies Q1 Results FY27 results be announced?
Ans. The Venus Remedies Q1 results date has not been officially announced yet. Q1 FY27 results for NSE-listed companies are typically declared shortly after Q1 FY27 ends, with the Venus Remedies Q1 results date disclosed via a board meeting notice on the NSE or BSE filing portal. Track the latest news on Venus Remedies Q1 results FY26-27 on the Univest Screener for timely updates.
